Latest From Novavax Inc.
Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.
Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?
Industry executives, consultants and analysts speculate on what they believe the big themes, trends and events will be this year.
Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.
- Drug Delivery
- Specialty Pharmaceuticals
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Novavax Inc.
- Senior Management
Stanley C Erck, Pres. & CEO
John J Trizzino, SVP, CBO & CFO
Gregory M Glenn, MD, Pres., R&D
Russell P Wilson, SVP, Bus. Dev.
Louis F Fries, MD, CMO
- Contact Info
Phone: (240) 268-2000
20 Firstfield Rd.
Gaithersburg, MD 20878
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.